<DOC>
	<DOCNO>NCT02671864</DOCNO>
	<brief_summary>Experimental data suggest GLP-1 promote endothelial cell growth angiogenesis may beneficial effect cardiovascular system harmful effect retina . This project investigate possible link incretin therapy Severe Diabetic Retinopathy . The prevalence severe DR patient expose incretin therapy ( GLP-1 analog DPP4 inhibitor ) compare non-exposed patient antidiabetic class .</brief_summary>
	<brief_title>Incretin-mimetic Hypoglycemic Drugs Severe Retinopathy</brief_title>
	<detailed_description>This study dedicate investigate impact routinely prescribed hypoglycaemic treatment prevalence severe retinopathy seek possible biomarkers severe retinopathy . Hypoglycemic treatment take patient prescribe usuel diabetogist context routine care . The study include T2D patient accord ADA criterion treat kind hypoglycemic treatment attend diabetes center ( One Marseille , Department Endocrinology , Hôpital Nord , Assistance Publique de Hôpitaux de Marseille , one Paris , Centre Universitaire du Diabète et de s ComplicationsHôpital Lariboisière , Université Paris 7 , Assistance Publique de Hôpitaux de Paris ) . It consist two visit : Visits1 `` Inclusion '' Visits 2 `` three year inclusion '' . In visit , investigator collect result eye examination ( fundus ) annual diabetes check include anthropometric data , routine biology , diabetes complication status well medication take patient ( past current ) . A bio-banking ( blood , urine hair ) also collect . Primary objective : compare prevalence severe DR patient expose incretin therapy ( GLP-1 analog DPP4 inhibitor ) non-exposed patient baseline . Secondary objective : To compare proportion patient worsen DR V1 ( inclusion ) V2 ( 3-yr treatment ) patient expose incretin-based therapy baseline v non-exposed patient : patient DR mild moderate non proliferative DR V1 progress severe DR V2 . To evaluate whether concentration angiogenic/inflammatory molecule circulate endothelial inflammatory cell associate severe DR relation use GLP-1 base therapy V1 V2 .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>T2D patient accord ADA criterion treat kind hypoglycaemic treatment Age 18 year Type 1 diabetes Patients cataract prevent DR grade Patients panretinal photocoagulation 6 year ago Documented pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Incretin-based therapy</keyword>
	<keyword>GLP1</keyword>
	<keyword>Angiogenesis Inflammation</keyword>
	<keyword>Hypoglycaemic treatment</keyword>
</DOC>